Novo Nordisk : NVO

All Novo Nordisk Articles

163 Articles

Austin Smith | Feb 9, 2026 at 11:59 AM EST

HIMs 22% Collapse Looks Like A ‘Buy The Dip’ Moment

Shares of Hims & Hers Health (NYSE:HIMS) plunged 22% at market open on Monday, February 9. The telehealth company pulled…

Douglas A. McIntyre | Feb 9, 2026 at 10:39 AM EST

Hims & Hers Falls Apart, Again

Hims & Hers Health (NASDAQ: HIMS) has had among the worst runs of any public company over the last year.…

Rich Duprey | Feb 4, 2026 at 2:39 PM EST

Eli Lilly Is Dominating the GLP-1 Wars as Novo Nordisk Sales Tank

The rivalry in the GLP-1 market between pharmaceutical leaders Eli Lilly (NYSE:LLY | LLY Price Prediction) and Novo Nordisk (NYSE:NVO)…

Austin Smith | Jan 23, 2026 at 10:36 AM EST

VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion

The VanEck Pharmaceutical ETF (NYSEARCA:PPH) has surged 26% over the past year, driven almost entirely by the weight-loss drug revolution.…

Joel South | Jan 21, 2026 at 8:20 AM EST

Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2026-2030 (Jan 2026)

Novo Nordisk sees the obesity drug market expanding to $100 billion by 2030. With promising new treatments in the pipeline,…

Ian Cooper | Dec 24, 2025 at 9:47 AM EST

Stock Market Live December 24, 2025: S&P 500 (SPY) at Record Highs

With the holidays upon us, markets aren’t moving much. Instead, many are taking time off to enjoy the holidays and…

Rich Duprey | Dec 23, 2025 at 1:23 PM EST

Novo Nordisk Strikes First With Oral Wegovy — But Can It Outrun Lilly’s Looming Pill?

Yesterday, the Food and Drug Administration (FDA) approved Novo Nordisk‘s (NYSE:NVO | NVO Price Prediction) Wegovy weight-loss pill, the first…

Ian Cooper | Dec 23, 2025 at 8:58 AM EST

Premarket Movers: Albemarle Gaining Momentum on Lithium Boom

Albemarle (NYSE: ALB | ALB Price Prediction) had an incredible year. Since bottoming out at around $50 in April, the…

Douglas A. McIntyre | Nov 14, 2025 at 4:13 PM EST

Retail Investors Really Don’t Like Novo Nordisk (NVO) Stock

Shares of Novo Nordisk A/S (NYSE: NVO | NVO Price Prediction) dropped 1.9%today, closing at $48.25, just a whisker above…

Omor Ibne Ehsan | Nov 11, 2025 at 10:07 AM EST

3 Buy-And-Forget Dividend Stocks With Snowballing Payouts

If the headline yield today is not something you’re concerned with, and you pay more attention to how fast a…

Trey Thoelcke | Nov 5, 2025 at 8:45 AM EST

Insiders Scoop Up Shares of This Biotech IPO, Energy Giant, and More

In the past week or so, a biotech and an energy infrastructure giant saw some huge insider buying. These were…

Rich Duprey | Nov 3, 2025 at 10:13 AM EST

Viking Therapeutics Could Be Pharma’s Next Big Buyout Target

The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments that…

Rich Duprey | Oct 22, 2025 at 11:48 AM EDT

Market Meltdown Coming? These 2 ETFs Are Ready to Surge If Stocks Tank

The U.S. stock market has delivered impressive gains for over a decade, but warning signs of a potential downturn are…

Rich Duprey | Oct 17, 2025 at 11:05 AM EDT

Is Trump Going to Kill the GLP-1 Cash Cow?

The Boom That Built Billion-Dollar Empires GLP-1 drugs have reshaped the pharmaceutical landscape, turning obesity and diabetes treatments into massive…

Rich Duprey | Oct 1, 2025 at 10:47 AM EDT

100% Pharmaceutical Tariffs Are Here. Time to Buy These 3 Drugmakers

Starting today, the U.S. imposed 100% tariffs on imports of branded or patented pharmaceutical products that President Trump announced last…

1 2 3 4 5 … 11

Novo Nordisk : NVO

All Novo Nordisk Articles

HIMs 22% Collapse Looks Like A ‘Buy The Dip’ Moment

Hims & Hers Falls Apart, Again

Eli Lilly Is Dominating the GLP-1 Wars as Novo Nordisk Sales Tank

VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion

Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2026-2030 (Jan 2026)

Stock Market Live December 24, 2025: S&P 500 (SPY) at Record Highs

Novo Nordisk Strikes First With Oral Wegovy — But Can It Outrun Lilly’s Looming Pill?

Premarket Movers: Albemarle Gaining Momentum on Lithium Boom

Retail Investors Really Don’t Like Novo Nordisk (NVO) Stock

3 Buy-And-Forget Dividend Stocks With Snowballing Payouts

Insiders Scoop Up Shares of This Biotech IPO, Energy Giant, and More

Viking Therapeutics Could Be Pharma’s Next Big Buyout Target

Market Meltdown Coming? These 2 ETFs Are Ready to Surge If Stocks Tank

Is Trump Going to Kill the GLP-1 Cash Cow?

100% Pharmaceutical Tariffs Are Here. Time to Buy These 3 Drugmakers

The “G-Wagon Loophole”: How Business Owners Write Off a $100,000 SUV the Year They Buy It

‘$13,426 of Stupid’: Dave Ramsey’s Blunt Advice to a Caller Who Maxed Out Credit Cards Flipping Pokemon Cards

The Next 30% Crash Will Happen. These 3 ETFs Mean You Won’t Panic-Sell at the Bottom

'$13,426 of Stupid': Dave Ramsey's Blunt Advice to a Caller Who Maxed Out Credit Cards Flipping Pokemon Cards

How Corporate Executives Stash $100,000+ Into a 401(k) Using the 415(c) Rule Most People Miss

The “G-Wagon Loophole”: How Business Owners Write Off a $100,000 SUV the Year They Buy It

‘$13,426 of Stupid’: Dave Ramsey’s Blunt Advice to a Caller Who Maxed Out Credit Cards Flipping Pokemon Cards

Novo Nordisk : NVO

All Novo Nordisk Articles

HIMs 22% Collapse Looks Like A ‘Buy The Dip’ Moment

Hims & Hers Falls Apart, Again

Eli Lilly Is Dominating the GLP-1 Wars as Novo Nordisk Sales Tank

VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion

Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2026-2030 (Jan 2026)

Stock Market Live December 24, 2025: S&P 500 (SPY) at Record Highs

Novo Nordisk Strikes First With Oral Wegovy — But Can It Outrun Lilly’s Looming Pill?

Premarket Movers: Albemarle Gaining Momentum on Lithium Boom

Retail Investors Really Don’t Like Novo Nordisk (NVO) Stock

3 Buy-And-Forget Dividend Stocks With Snowballing Payouts

Insiders Scoop Up Shares of This Biotech IPO, Energy Giant, and More

Viking Therapeutics Could Be Pharma’s Next Big Buyout Target

Market Meltdown Coming? These 2 ETFs Are Ready to Surge If Stocks Tank

Is Trump Going to Kill the GLP-1 Cash Cow?

100% Pharmaceutical Tariffs Are Here. Time to Buy These 3 Drugmakers

The “G-Wagon Loophole”: How Business Owners Write Off a $100,000 SUV the Year They Buy It

‘$13,426 of Stupid’: Dave Ramsey’s Blunt Advice to a Caller Who Maxed Out Credit Cards Flipping Pokemon Cards

The Next 30% Crash Will Happen. These 3 ETFs Mean You Won’t Panic-Sell at the Bottom

Featured Reads

'$13,426 of Stupid': Dave Ramsey's Blunt Advice to a Caller Who Maxed Out Credit Cards Flipping Pokemon Cards

How Corporate Executives Stash $100,000+ Into a 401(k) Using the 415(c) Rule Most People Miss